Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 190.91M | 36.55M | 8.78M | 12.40M | 0.00 | 0.00 |
Gross Profit | 187.58M | 32.11M | 8.78M | 8.87M | -2.23M | -1.93M |
EBITDA | 39.79M | -99.19M | -112.30M | -102.81M | -83.58M | -50.32M |
Net Income | 50.27M | -88.98M | -104.70M | -93.11M | -84.71M | -50.61M |
Balance Sheet | ||||||
Total Assets | 406.89M | 271.56M | 228.34M | 256.07M | 238.87M | 297.93M |
Cash, Cash Equivalents and Short-Term Investments | 357.32M | 216.90M | 201.39M | 229.59M | 219.81M | 287.31M |
Total Debt | 2.35M | 2.32M | 2.06M | 2.36M | 1.51M | 80.00K |
Total Liabilities | 56.81M | 42.53M | 68.78M | 71.22M | 21.09M | 11.85M |
Stockholders Equity | 350.07M | 229.02M | 159.56M | 184.85M | 217.78M | 286.08M |
Cash Flow | ||||||
Free Cash Flow | 69.20M | -87.05M | -82.68M | -35.83M | -68.11M | -43.27M |
Operating Cash Flow | 69.54M | -86.85M | -81.07M | -31.87M | -66.91M | -42.22M |
Investing Cash Flow | -103.83M | -107.47M | 105.95M | -45.88M | -76.43M | -1.05M |
Financing Cash Flow | 130.75M | 131.09M | 53.01M | 46.41M | 1.28M | 108.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $626.77M | 14.59 | 20.50% | ― | 2333.50% | ― | |
59 Neutral | $519.43M | ― | ― | ― | ― | ||
54 Neutral | $622.35M | ― | -45.46% | ― | -78.26% | 15.41% | |
54 Neutral | $622.74M | ― | 181.41% | ― | 3055.71% | -18.80% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% | |
34 Underperform | $407.93M | ― | -45.82% | ― | ― | 10.38% | |
33 Underperform | $719.52M | ― | -71.44% | ― | ― | 19.94% |
On June 3, 2025, Stoke Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were adopted. These included the election of three Class III directors, the ratification of KPMG LLP as the independent registered public accounting firm for 2025, and the approval of executive compensation and its future advisory vote frequency. These decisions are expected to influence the company’s governance and operational strategies moving forward.
The most recent analyst rating on (STOK) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.
Stoke Therapeutics announced the initiation of their Phase 3 EMPEROR study for zorevunersen, with the first U.S. sites starting in May 2025. This study aims to evaluate the effectiveness of zorevunersen as a potential first-in-class therapy for Dravet syndrome, a severe genetic epilepsy. The announcement marks a significant step in the company’s efforts to address unmet medical needs in this area, potentially impacting their market positioning and offering hope for stakeholders involved in Dravet syndrome treatment.
The most recent analyst rating on (STOK) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.